전체 프로그램

ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved212 programs
CGTLimited DatastaleChinese PLA General HospitalPhase 2

anti-CD19/22-CAR vector-transduced T cells (anti-CD19/22-CAR vector-transduced T cells)

Hematopoietic/Lymphoid Cancer; Adult Acute Lymphoblastic Leukemia in Remission · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 1Status Active
CGTLimited DatastaleGracell Biotechnologies (Shangh…Preclinical

CHT105 (anti-CD19/70 CAR T cells, anti-CD19/70 CAR T cells (CHT105))

Systemic Lupus Erythematosus; Lupus Nephritis · CD19

#CD19#CGT#Preclinical#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleJieyang People's HospitalPhase 1

anti-CD19/BCMA CAR NK cells (anti-CD19/BCMA CAR NK cells)

IgA Nephropathy (IgAN) · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Discontinued
CGTLimited DatastalePeng LiuPhase 1

anti-CD19/BCMA CAR-T cells (anti-CD19/BCMA CAR-T cells)

Multiple Myeloma in Relapse; Multiple Myeloma Progression · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleRui Therapeutics Co., LtdPhase 1

anti-CD19/BCMA U CAR T (anti-CD19/BCMA U CAR T)

Relapsed/Refractory Immune Nephropathy; Relapsed/Refractory Immune-mediated Kidney Disease · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleMarino Biotechnology Co., Ltd.Phase 1

autologous anti-CD19 CAR T cells (autologous anti-CD19 CAR T cells)

B-cell Lymphoma · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleShenzhen Geno-Immune Medical In…Phase 2

bi-4SCAR CD19/79b T cells (bi-4SCAR CD19/79b T cells)

B Cell Malignancies · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleZhujiang HospitalPhase 1

humanized CD19 CAR-T Cells with TLR2 (humanized CD19 CAR-T Cells with TLR2)

B Lymphoblastic Leukemia/Lymphoma · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleMarino Biotechnology Co., Ltd.Phase 1

iPD1 CD19 eCAR T cells (iPD1 CD19 eCAR T cells)

Relapsed or Refractory B-cell Lymphoma · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 1

mCD19-CAR-CD28-CD3-zeta. (anti-CD19 CAR, mCD19-CAR-CD28-CD3-zeta., mCD19-CAR-CD28-CD3-zeta.(anti-CD19 CAR) retroviral vector-transduced allogeneic peripheral blood lymphocytes (PBL))

Hematologic Malignancies; Hematologic Neoplasms · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleThe First Affiliated Hospital o…Phase 2

ssCART-19 cells combined with CD19+ feeding T cells (FTCs, ssCART-19 cells combined with CD19+ feeding T cells, ssCART-19 cells combined with CD19+ feeding T cells (FTCs) infusion)

Acute Lymphoblastic Leukemia, Adult B-Cell · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing GoBroad HospitalPhase 2

umbilical cord blood CD19-BCMA CAR-T cells infusion (umbilical cord blood CD19-BCMA CAR-T cells infusion)

Refractory Lupus Nephritis; Systemic Sclerosis · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting

11 / 11 pages

← PreviousNext →